The Alzheimer`s Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, `Eisai`), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, `Biogen`) announced today that a new Phase III clinical study （AHEAD 3-45) of BAN2401, an anti-amyloid beta (Aβ) protofibril antibody, has been initiated in the United States of America for individuals with preclinical Alzheimer`s disease (AD), meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains. Currently, BAN2401 is being studied in a pivotal Phase III clinical study in symptomatic early AD (Clarity AD), following the...
|
